SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-017141
Filing Date
2024-04-02
Accepted
2024-04-02 07:10:35
Documents
14
Period of Report
2024-04-02
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20025692_8k.htm   iXBRL 8-K 36901
2 EXHIBIT 99.1 ef20025692_ex99-1.htm EX-99.1 29894
  Complete submission text file 0001140361-24-017141.txt   213461

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20240402.xsd EX-101.SCH 3862
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20240402_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20240402_pre.xml EX-101.PRE 16042
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20025692_8k_htm.xml XML 4208
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

IRS No.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 24812201
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)